Single User License
INR 102255
Site License
INR 204510
Corporate User License
INR 306765

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Actelion Ltd-Product Pipeline Review-2015

Actelion Ltd-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Actelion Ltd-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Actelion Ltd-Product Pipeline Review-2015', provides an overview of the Actelion Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actelion Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Actelion Ltd including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Actelion Ltd's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Actelion Ltd's pipeline products

Reasons To Buy

Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Actelion Ltd in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Actelion Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Actelion Ltd and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actelion Ltd

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Actelion Ltd and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Actelion Ltd Snapshot 6

Actelion Ltd Overview 6

Key Information 6

Key Facts 6

Actelion Ltd-Research and Development Overview 7

Key Therapeutic Areas 7

Actelion Ltd-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Actelion Ltd-Pipeline Products Glance 14

Actelion Ltd-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Actelion Ltd-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Actelion Ltd-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Actelion Ltd-Drug Profiles 20

selexipag 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

cadazolid 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

macitentan 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ponesimod 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

miglustat 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Agonize S1P1 Receptor for Systemic Lupus Erythematosus 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ACT-246475 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ACT-281959 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ACT-389949 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ACT-451840 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ACT-462206 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

lucerastat 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule for Cardiovascular Disorders 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule for Neurological Disorders 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecule for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Actelion Ltd-Pipeline Analysis 41

Actelion Ltd-Pipeline Products by Target 41

Actelion Ltd-Pipeline Products by Route of Administration 42

Actelion Ltd-Pipeline Products by Molecule Type 43

Actelion Ltd-Pipeline Products by Mechanism of Action 44

Actelion Ltd-Recent Pipeline Updates 45

Actelion Ltd-Dormant Projects 51

Actelion Ltd-Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

almorexant 52

clazosentan 52

palosuran 52

Actelion Ltd-Company Statement 53

Actelion Ltd-Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Actelion Ltd, Key Information 6

Actelion Ltd, Key Facts 6

Actelion Ltd-Pipeline by Indication, 2015 9

Actelion Ltd-Pipeline by Stage of Development, 2015 10

Actelion Ltd-Monotherapy Products in Pipeline, 2015 11

Actelion Ltd-Partnered Products in Pipeline, 2015 12

Actelion Ltd-Partnered Products/ Combination Treatment Modalities, 2015 13

Actelion Ltd-Pre-Registration, 2015 14

Actelion Ltd-Phase III, 2015 15

Actelion Ltd-Phase II, 2015 16

Actelion Ltd-Phase I, 2015 17

Actelion Ltd-Preclinical, 2015 18

Actelion Ltd-Discovery, 2015 19

Actelion Ltd-Pipeline by Target, 2015 41

Actelion Ltd-Pipeline by Route of Administration, 2015 42

Actelion Ltd-Pipeline by Molecule Type, 2015 43

Actelion Ltd-Pipeline Products by Mechanism of Action, 2015 44

Actelion Ltd-Recent Pipeline Updates, 2015 45

Actelion Ltd-Dormant Developmental Projects,2015 51

Actelion Ltd-Discontinued Pipeline Products, 2015 52

Actelion Ltd, Subsidiaries 54

List of Figures

Actelion Ltd-Pipeline by Top 10 Indication, 2015 8

Actelion Ltd-Pipeline by Stage of Development, 2015 10

Actelion Ltd-Monotherapy Products in Pipeline, 2015 11

Actelion Ltd-Partnered Products in Pipeline, 2015 12

Actelion Ltd-Pipeline by Top 10 Target, 2015 41

Actelion Ltd-Pipeline by Top 10 Route of Administration, 2015 42

Actelion Ltd-Pipeline by Top 10 Molecule Type, 2015 43

Actelion Ltd-Pipeline Products by Top 10 Mechanism of Action, 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Actelion Ltd; Actelion Ltd - Key Therapeutics; Actelion Ltd - Pipeline Overview and Promising Molecules; Actelion Ltd - News; Actelion Ltd - Latest Updates; Actelion Ltd - Pipeline; Actelion Ltd - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com